Professor of Respiratory Medicine
Professor Pavord has a particular interest in asthma, chronic pulmonary disease and chronic cough. He is an internationally renowned researcher in these areas and has played a lead role in developing three of the most promising emerging treatments. He has published 350 scientific papers, including three of the 20 most cited papers in the field in the last 10 years. He has an H-index of 74. His main contribution has been to develop new methods to assess and treat airway inflammation and airway diseases.
He has been joint Chief Medical Advisor to Asthma UK since May 2008 and joint Editor of Thorax since 2010.
in 2016 Professor Pavord was awarded The ERS Gold Medal in Asthma in recognition of his outstanding contribution in the field of asthma research.
Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations.
Djamin RS. et al, (2019), Respir Med, 154, 27 - 33
Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.
Beasley R. et al, (2019), N Engl J Med, 380, 2020 - 2030
Asthma progression and mortality: The role of inhaled corticosteroids.
O'Byrne P. et al, (2019), Eur Respir J
Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies.
Pavord ID. and Hanania NA., (2019), J Allergy Clin Immunol Pract, 7, 1430 - 1436
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.
Singh D. et al, (2019), Eur Respir J, 53